Ongoing discussions about regulatory flexibility for accelerated approval of rare disease drugs for neurodegenerative conditions.
2025 · 1st Quarter (Jan 1 - Mar 31)
CLENE NANOMEDICINE
Filed by THE MIZEUR GROUP, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- 1st Quarter - Report
- Posted
- May 20, 2025
- Income
- $5,000.00
- Expenses
- Not reported
- Registrant
- THE MIZEUR GROUP, LLC
- Client
- CLENE NANOMEDICINE
- Filing UUID
- af684d97-6e25-4fc8-b0d3-e270b681fed4
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.